| Literature DB >> 35343414 |
Omer Atac1, Volkan Aydin2, Selma Karabey3, Osman Hayran1, Ahmet Akici4.
Abstract
AIM: To compare the competencies of primary care physicians (PCPs) with poor and good prescribing performance in frequently encountered indications.Entities:
Keywords: diagnosis; pharmacotherapy; physicians; prescribing performance; primary care; rational use of medicine
Mesh:
Year: 2022 PMID: 35343414 PMCID: PMC8991858 DOI: 10.1017/S1463423622000111
Source DB: PubMed Journal: Prim Health Care Res Dev ISSN: 1463-4236 Impact factor: 1.458
Figure 1.Selection cascade of the prescriber groups.
*Poor and good prescribers represented at the highest and lowest quartile of primary care physicians in at least two of three selected WHO/INRUD criteria, respectively.
The comparison of the performances of the study groups for selected WHO/INRUD drug-use indicators
| Poor prescribers | Good prescribers |
| ||
|---|---|---|---|---|
|
| ||||
|
| Average number of medicines per encounter, n (±SD) | 2.35 ± 1.87 | 1.96 ± 1.45 |
|
| Average medicine cost per encounter, US$ (±SD) | 43.99 ± 63.05 | 11.45 ± 45.00 |
| |
| Encounters with an antibiotic prescribed, % | 3.2 | 1.1 |
| |
|
| Average number of medicines per encounter, n (±SD) | 2.94 ± 1.49 | 2.44 ± 0.90 |
|
| Average medicine cost per encounter, US$ (±SD) | 11.47 ± 26.05 | 7.28 ± 6.36 |
| |
| Encounters with an antibiotic prescribed, % | 75.3 | 73.9 |
| |
|
| Average number of medicines per encounter, n (±SD) | 3.06 ± 1.31 | 2.52 ± 0.95 |
|
| Average medicine cost per encounter, US$ (±SD) | 13.11 ± 20.69 | 8.40 ± 6.94 |
| |
| Encounters with an antibiotic prescribed, % | 86.8 | 79.9 |
| |
|
| Average number of medicines per encounter, n (±SD) | 2.02 ± 1.00 | 1.88 ± 0.90 |
|
| Average medicine cost per encounter, US$ (±SD) | 8.91 ± 16.68 | 6.85 ± 16.59 |
| |
| Encounters with an antibiotic prescribed, % | 91.8 | 86.0 |
| |
|
| Average number of medicines per encounter, n (±SD) | 2.76 ± 2.02 | 2.17 ± 1.59 |
|
| Average medicine cost per encounter, US$ (±SD) | 47.13 ± 158.47 | 20.95 ± 5.15 |
| |
| Encounters with an antibiotic prescribed, % | 23.1 | 9.0 |
| |
|
| ||||
|
| Average number of medicines per encounter, n (±SD) | 3.17 ± 0.99 | 1.96 ± 0.64 |
|
| Average medicine cost per encounter, US$ (±SD) | 40.39 ± 26.91 | 16.80 ± 12.44 |
| |
| Encounters with an antibiotic prescribed, % | 6.1 | 2.8 |
| |
|
| Average number of medicines per encounter, n (±SD) | 2.48 ± 0.50 | 2.07 ± 0.32 |
|
| Average medicine cost per encounter, US$ (±SD) | 14.21 ± 7.09 | 9.51 ± 6.14 |
| |
| Encounters with an antibiotic prescribed, % | 1.1 | 0.5 |
| |
|
| Average number of medicines per encounter, n (±SD) | 2.94 ± 1.15 | 1.76 ± 0.53 |
|
| Average medicine cost per encounter, US$ (±SD) | 19.94 ± 11.16 | 9.13 ± 6.48 |
| |
| Encounters with an antibiotic prescribed, % | 25.3 | 7.9 |
| |
|
| Average number of medicines per encounter, n (±SD) | 2.60 ± 1.17 | 1.64 ± 0.49 |
|
| Average medicine cost per encounter, US$ (±SD) | 16.41 ± 19.85 | 5.25 ± 4.87 |
| |
| Encounters with an antibiotic prescribed, % | 18.7 | 5.0 |
| |
|
| Average number of medicines per encounter, n (±SD) | 3.02 ± 0.95 | 1.60 ± 0.55 |
|
| Average medicine cost per encounter, US$ (±SD) | 31.50 ± 18.10 | 11.83 ± 11.57 |
| |
| Encounters with an antibiotic prescribed, % | 14.9 | 1.5 |
| |
Delta calculation was made by considering good prescribers’ data compared to poor prescribers’. SD, standard deviation.
The comparison of the prescriptions’ compliance to treatment guidelines for disease-based diagnoses by the study groups
| Poor prescribers | Good prescribers | |||||
|---|---|---|---|---|---|---|
| Indications and guideline compliance | n | % | n | % | p | |
|
|
| 24 577 | 34.8 | 19 629 | 40.8 |
|
|
| 45 996 | 65.2 | 28 534 | 59.2 | ||
|
| 70 573 | 100.0 | 48 163 | 100.0 | ||
|
|
| 14 579 | 50.7 | 26 868 | 57.9 |
|
|
| 14 186 | 49.3 | 19 548 | 42.1 | ||
|
| 28 765 | 100.0 | 46 416 | 100.0 | ||
|
|
| 7,746 | 43.6 | 5,408 | 46.4 |
|
|
| 10 019 | 56.4 | 6,236 | 53.6 | ||
|
| 17 765 | 100.0 | 11 644 | 100.0 | ||
Figure 2.The distribution of antibiotic subgroups in prescriptions of the study groups.